Skip to main content
Premium Trial:

Request an Annual Quote

Pathogen Disease Sample Prep Firm NanoMR Raises $13M in Series B

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NanoMR, a company developing diagnostics for the identification of pathogens, today announced it has raised $13 million in a Series B financing round.

The money will be used to develop commercial instruments for the clinical microbiology market, conduct clinical studies, and prepare for a product launch, the Albuquerque, NM-based firm said.

Excel Venture Management led the round and was joined by Healthcare Ventures and existing investors vSpring Capital, Dow Chemical, and Sun Mountain Capital. Steve Gullans, a managing director at Excel, and Gus Lawlor, a managing director at Healthcare Ventures, will join NanoMR's board, the firm said.

The company has developed immunomagnetic technology that isolates pathogens directly from blood in less than 30 minutes, which in turns allows for the identification of infectious organisms by molecular diagnostic methods, such as PCR or DNA hybridization, in less than two hours. By comparison, blood-based culture methods, the current standard, takes at least 48 hours, the firm noted.

According to NanoMR, the delay in detection and treatment of bloodstream infections results in more than 250,000 deaths each year in the US and costs the average hospital more than $7.7 million each year.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.